Date: 2017-02-27
Type of information: Collaboration agreement
Compound:
Company: Recordati (Italy) Meyer Hospital (Italy)
Therapeutic area: Rare diseases - Ophtalmological diseases
Type agreement: collaboration
Action mechanism:
Disease: retinopathy of prematurity
Details:
- • On February 27, 2017, Recordati announced the signing of an exclusive worldwide licensing agreement covering the know-how developed by the Meyer Hospital in Florence (Italy) for the development of a treatment for pre-term babies affected by retinopathy of prematurity.
- The treatment is currently being investigated in a phase II clinical trial by the Meyer Hospital, while Recordati will complete the clinical development and the regulatory steps necessary to obtain the marketing approval for the drug. Furthermore, within the deal, Recordati shall support other Meyer projects in the rare disease area over a period of three years based on a mutually agreed plan.
Retinopathy of prematurity is a potentially blinding eye disorder that primarily affects premature infants weighing about 1.25 kg or less that are born before 31 weeks of gestation. The smaller a baby is at birth, the more likely that baby is to develop this disorder.
Financial terms:
Latest news:
Is general: Yes
